Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

NDAQ:LMNL - Post Discussion

Liminal BioSciences Inc. > Ya good read from the website ...
View:
Post by GoBBs on Jun 04, 2020 10:28pm

Ya good read from the website ...

Highlights:

As of March 31st2020 (in Canadian $):•Working capital of $41M  ...
*This was 2 months ago ...so they have how much now ??? 20M ?
Comment by sah1 on Jun 05, 2020 4:38am
Gobbs, we already knew what the cash position was at the end of March. So nothing newsworthy there. What is interesting for me is the the apparent change of strategy for the roll out of Ryplazim. In the Q1 MDA and the annual security exchange filings, it is made clear that the company would not explore further applications of Ryplazim or any other plasma protein for that matter. Now the company ...more  
Comment by GoBBs on Jun 05, 2020 7:50am
yes they clearly indicated they would exit plasma therapies after Ryplazim ..now they are talking wound healing ...sounds like they are struggling to get a partner and need a better story. Who knows I don't believe one word of what they say anyway.By the time they file, fda accepts it, reviews it, approves it(or not) and they go to market or fail were talking fall 2021. Way better places to ...more  
Comment by sah1 on Jun 05, 2020 8:55am
Gobbs, you may be right that the company is finding it difficult to find a partner or marketing collaboration and a change of story is needed. What I hope for is that a different type of partnership has presented itself - one that will capitalise better on the previous work done by the company in identifying both new acute and also wound healing applications for Ryplazim. Perhaps a private ...more  
Liminal BioSciences Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities